Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641466 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
A Phase 3 study of Menstrual Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 723
- Enrollment target
- 20
- Study locations
NCT06641466 is a Phase 3 study of Menstrual Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 723 participants, above the 42-participant average among 3 other Menstrual Migraine trials with a reported enrollment target (1621% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06641466, a Phase 3 study of Menstrual Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 723 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Conditions Studied
Interventions
- DRUG Standard of Care
- DRUG Placebo Comparator
- DRUG Rimegepant
Study Locations (20)
Arizona
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic Specialty Building - Phoenix
- Mayo Clinic Arizona - Scottsdale
California
- Hope Clinical Research, Inc. - Canoga Park
- Axiom Research - Colton
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- VIN - Aventura - Aventura
- Velocity Clinical Research, Hallandale Beach - Hallandale
- Jacksonville Center for Clinical Research - Jacksonville
Georgia
- Urban Family Practice Associates - Marietta
- Clinical Research Atlanta - Stockbridge
Missouri
- Clinvest Headlands Llc - Springfield
- St. Charles Clinical Research - Weldon Spring
New York
- Rochester Clinical Research, LLC - Rochester
- Montefiore Medical Center - The Bronx
Idaho
- St Luke's Clinic - Neurology - Meridian
Indiana
- Alliance for Multispecialty Research - Medisphere Medical Research Center - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 723 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06641466
The ClinicalTrials.gov registry entry for NCT06641466 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 723 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 42-participant average among 3 other Menstrual Migraine trials with a reported enrollment target (1621% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Menstrual Migraine appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT06641466 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06641466 about?
NCT06641466 is a clinical study titled "A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine". The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
What is the current status of trial NCT06641466?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 723 participants. The study started on 2025-03-11. Estimated completion is 2027-03-30.
What conditions does trial NCT06641466 study?
This clinical trial studies the following conditions: Menstrual Migraine.
What interventions are being tested in trial NCT06641466?
The interventions under investigation include: Standard of Care (DRUG), Placebo Comparator (DRUG), Rimegepant (DRUG).
Who is sponsoring clinical trial NCT06641466?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641466 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menstrual Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine
COMPLETED · Phase 4
-
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.